Lv61
3056 积分 2024-06-07 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
27天前
已完结
Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding
1个月前
已完结
Adverse Events in Targeted Radionuclide Therapy
1个月前
已完结
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
2个月前
已完结
Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies
2个月前
已关闭
Preclinical Development of 3BP-3940, a Fibroblast Activation Protein–Targeted Cyclic Peptide–Based Radiotheranostic for Imaging and Therapy
2个月前
已完结
Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers
2个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
3个月前
已关闭
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
3个月前
已完结
Actinium-225 Targeted Agents: Where Are We Now?
3个月前
已完结
皖公网安备34019202002308
